📌 Key Takeaways
- RHA Dynamic Volume, co-developed by Teoxane and Revance, received FDA approval on January 13, 2026 for cheek augmentation and midface volume deficiency in adults 22 years and older
- The defining feature is PNT (Preserved Network Technology)—a patented manufacturing process that maintains hyaluronic acid’s natural structure without heat, creating a filler that “moves with facial expressions”
- 52-week Phase III trial demonstrated non-inferiority to Juvéderm Voluma XC, the current market leader, with over 10 years of post-market safety data in Europe
“After getting filler, my face looks unnatural when I smile.”
If you’ve ever received dermal filler treatment, you may recognize this concern.
Hyaluronic acid fillers can appear natural in a resting face, yet create visible distortion during dynamic movement—when you laugh, speak, or express emotion.
RHA Dynamic Volume addresses this problem through engineering.
INDEX
What Is RHA Dynamic Volume?
A Geneva-based pharmaceutical company specializing in aesthetic medicine. Teoxane focuses exclusively on hyaluronic acid filler research and development, holding significant market share in Europe. The company developed the proprietary RHA (Resilient Hyaluronic Acid) Collection and partners with Revance for U.S. distribution.
📊 RHA Dynamic Volume: Core Data
PNT Technology: What Makes It Different
Conventional hyaluronic acid fillers use BDDE (butanediol diglycidyl ether) as a crosslinking agent combined with heat processing. This manufacturing approach alters hyaluronic acid’s natural structure, creating firmness but reducing adaptability.
RHA Dynamic Volume’s PNT technology represents a departure from this standard.
A manufacturing process that eliminates heat treatment and employs uniform crosslinking to preserve hyaluronic acid’s natural network structure as intact as possible.The result: a gel with both high dynamic strength (resistance to deformation under stress) and extensibility (ability to stretch and return). This dual characteristic enables the filler to “maintain structure at rest while adapting flexibly to facial movement.”
Clinical Trial Results: Head-to-Head With Voluma XC
The 52-week Phase III clinical trial supporting FDA approval included a direct comparison with Juvéderm Voluma XC, currently the market-leading midface filler.
📊 52-Week Phase III Trial: Primary Outcomes
Sandra Chennoufi, Chief Scientific Officer for Europe, stated:
Sandra Chennoufi, Chief Scientific Officer, Teoxane, January 13, 2026
Implications for Global Aesthetic Medicine
RHA Dynamic Volume is not yet approved in Japan or several other markets. However, the concept of “dynamic filler design” signals a directional shift in the global filler industry.
“Unnatural appearance when smiling after filler”—engineering has provided an answer to this complaint.This shifts the patient decision framework from “whether to get filler” to “which filler design to choose.”While RHA Dynamic Volume remains unavailable in many markets, the evaluative lens of “does this filler accommodate facial dynamics?” is already relevant. Asking during consultation, “How does this filler respond to facial movement?” may become a new standard in provider selection.
Summary
- RHA Dynamic Volume received FDA approval (January 13, 2026) featuring PNT technology designed to move with facial expressions
- 52-week Phase III trial demonstrated non-inferior efficacy and safety versus Juvéderm Voluma XC
- Heat-free, uniform crosslinking manufacturing preserves hyaluronic acid’s natural structure during injection
- Not yet approved in Japan or several other markets—but the evaluative framework of “dynamic filler design” is worth understanding now
Frequently Asked Questions
Sources:
Revance and Teoxane official press release “Revance and Teoxane Announce the FDA Approval of RHA® Dynamic Volume for Midface Contour Deficiencies” PR Newswire, January 13, 2026 / MedEsthetics “FDA Approves RHA Dynamic Volume for Midface Contouring” January 13, 2026 / Dermatology Times “ICYMI: FDA Clears RHA Dynamic Volume for Midface Augmentation” May 2026 / Flégeau K, et al. “Safety and Performance of RHA4 in the Midface Using the Multilayering Technique” Plast Reconstr Surg Glob Open 2025;13(2):e6560
